Bristol-Myers Squibb Company (BMY)
Receivables turnover
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Revenue | US$ in thousands | 48,300,000 | 45,006,000 | 46,159,000 | 46,385,000 | 42,518,000 |
| Receivables | US$ in thousands | 10,747,000 | 10,921,000 | 9,886,000 | 9,369,000 | 8,501,000 |
| Receivables turnover | 4.49 | 4.12 | 4.67 | 4.95 | 5.00 |
December 31, 2024 calculation
Receivables turnover = Revenue ÷ Receivables
= $48,300,000K ÷ $10,747,000K
= 4.49
The receivables turnover ratio for Bristol-Myers Squibb Company has exhibited a slight decrease over the past five years. Beginning with 5.00 on December 31, 2020, the ratio decreased to 4.95 on December 31, 2021, further declining to 4.67 on December 31, 2022. Subsequently, the ratio decreased to 4.12 on December 31, 2023, before experiencing a slight increase to 4.49 on December 31, 2024. The decreasing trend in the receivables turnover ratio indicates that the company is taking longer to collect its accounts receivable, which could potentially signal issues with credit policies or the collection process. Further investigation into the reasons behind this trend would be advisable to ensure efficient management of receivables.
Peer comparison
Dec 31, 2024